We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
+29.83%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$2.21B
AUM Growth
+$276M
Cap. Flow
-$34.2M
Cap. Flow %
-1.55%
Top 10 Hldgs %
39.41%
Holding
128
New
23
Increased
32
Reduced
32
Closed
15

Top Buys

Rank Stock Value
1
TRAX
First Tracks Biotherapeutics
TRAX
+$38M
2
ROIV icon
Roivant Sciences
ROIV
+$28.1M
3
AVTX icon
Avalo Therapeutics
AVTX
+$24.6M
4
RVMD icon
Revolution Medicines
RVMD
+$21.9M
5
INSM icon
Insmed
INSM
+$20.6M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$55.6M
2
ACLX
Arcellx
ACLX
+$41.7M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$34.2M
4
TERN
Terns Pharmaceuticals
TERN
+$29.7M
5
APGE icon
Apogee Therapeutics
APGE
+$26.8M

Sector Composition

Rank Sector Weight
1 Healthcare 89.73%
2 Miscellaneous 9.21%
3 Financials 1.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ROIV icon
1
Roivant Sciences
ROIV
$24.9B
$133M 6%
3,750,000
+950,000
+34% +$28.1M
APGE icon
2
Apogee Therapeutics
APGE
$10.2B
$131M 5.92%
987,000
-297,926
-23% -$26.8M
SYRE icon
3
Spyre Therapeutics
SYRE
$7.69B
$114M 5.13%
1,279,134
– –
XENE icon
4
Xenon Pharmaceuticals
XENE
$5.85B
$96.3M 4.35%
1,595,000
-80,000
-5% -$4.44M
ERAS icon
5
Erasca
ERAS
$5.69B
$96.2M 4.35%
5,250,000
-100,000
-2% -$1.43M
INSM icon
6
Insmed
INSM
$27.7B
$69.3M 3.13%
650,000
+170,000
+35% +$20.6M
PRAX icon
7
Praxis Precision Medicines
PRAX
$9.92B
$61.9M 2.8%
185,000
+15,000
+9% +$4.75M
ALKS icon
8
Alkermes
ALKS
$7.86B
$58.9M 2.66%
1,125,000
-225,000
-17% -$8.79M
ORKA
9
Oruka Therapeutics
ORKA
$6.02B
$56.2M 2.54%
590,000
+90,327
+18% +$6.02M
ANAB icon
10
AnaptysBio
ANAB
$1.7B
$55.8M 2.52%
826,109
-113,891
-12% -$6.9M
AVTX icon
11
Avalo Therapeutics
AVTX
$1.02B
$53.6M 2.42%
2,900,000
+1,559,160
+116% +$24.6M
CYTK icon
12
Cytokinetics
CYTK
$10.3B
$46.9M 2.12%
550,000
-150,483
-21% -$10.8M
RVMD icon
13
Revolution Medicines
RVMD
$45.2B
$46.8M 2.12%
250,000
+150,000
+150% +$21.9M
ABVX
14
Abivax
ABVX
$9.95B
$44M 1.99%
330,000
-75,000
-19% -$8.49M
TRAX
15
First Tracks Biotherapeutics
TRAX
$1.52B
$40.9M 1.85%
+2,032,012
New +$38M
DNTH icon
16
Dianthus Therapeutics
DNTH
$6.03B
$39M 1.76%
400,000
+50,000
+14% +$4.37M
STRO icon
17
Sutro Biopharma
STRO
$341M
$38.9M 1.76%
1,172,487
+102,968
+10% +$3.21M
MRNA icon
18
PUT
Moderna
MRNA
$59.4B
$35M 1.58%
+500,000
New +$25.9M
NUVL
19
DELISTED
Nuvalent
NUVL
$34M 1.54%
275,000
-25,000
-8% -$2.69M
TRVI icon
20
Trevi Therapeutics
TRVI
$2.43B
$33.6M 1.52%
1,800,172
-200,000
-10% -$2.91M
MRNA icon
21
CALL
Moderna
MRNA
$59.4B
$33.3M 1.5%
475,000
-325,000
-41% -$16.8M
ARKG icon
22
CALL
ARK Genomic Revolution ETF
ARKG
$2B
$31.5M 1.43%
+750,000
New +$23.9M
OVID icon
23
Ovid Therapeutics
OVID
$543M
$27.3M 1.23%
10,144,562
-491,756
-5% -$1.27M
LXEO icon
24
Lexeo Therapeutics
LXEO
$397M
$27M 1.22%
5,807,611
+757,400
+15% +$4.1M
CLDX icon
25
Celldex Therapeutics
CLDX
$3.09B
$26M 1.18%
700,000
+200,000
+40% +$6.46M
1
2 3 4 5

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q2 2026 Portfolio in Review

As of Q2 2026, Affinity Asset Advisors held 128 positions worth $2.21B, up 14% from $1.94B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Affinity Asset Advisors's Q2 2026 filing shows 23 new, 32 increased, 32 reduced and 15 closed positions. Its largest new stake was First Tracks Biotherapeutics: 2,032,012 shares worth $40.9M. The largest sale was Centessa Pharmaceuticals, an estimated $55.6M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Financials.

  • Affinity Asset Advisors's largest Q2 2026 buy was First Tracks Biotherapeutics: 2,032,012 shares worth $40.9M.
  • Affinity Asset Advisors added most to Roivant Sciences in Q2 2026, an estimated $28.1M increase.
  • Affinity Asset Advisors's biggest Q2 2026 reduction was Teva Pharmaceuticals, cutting an estimated $34.2M.
  • Affinity Asset Advisors fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $55.6M.
  • Affinity Asset Advisors's ten largest holdings make up 39% of its $2.21B portfolio in Q2 2026.
  • Affinity Asset Advisors opened 23 new positions and closed 15 in Q2 2026.
  • Affinity Asset Advisors's portfolio value rose 14% quarter-over-quarter to $2.21B.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.